Status:
RECRUITING
The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Pancreas Cancer
Chemotherapy
Eligibility:
All Genders
18+ years
Brief Summary
This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.
Eligibility Criteria
Inclusion
- Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021.
- \-
Exclusion
- Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days.
- \-
Key Trial Info
Start Date :
October 7 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2024
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT06208436
Start Date
October 7 2023
End Date
February 28 2024
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jihui
Tianjin, Tianjin Municipality, China, 300202